A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.

A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan 120mg/Atorvastatin 40mg and Co-administration of Fimasartan 120mg and Atorvastatin 40mg in Healthy Male Volunteers.

The purpose of this study is to evaluate the Pharmacokinetics and Safety / Tolerability of Fimasartan and Atorvastatin in Healthy Male volunteers.

This is a randomized, open-label, single dose, 3x3 partial replicated crossover study to evaluate the pharmacokinetics and safety/tolerability. Within each period, randomized subjects will be 2 dosing regimens with a fixed dose combination of Fimasartan/Atorvastatin and co-administration of Fimasartan and Atorvastatin.

Inclusion Criteria:

• A Healthy male aged 19-50 years
• Body weight is over 55kg and BMI 18 ~ 27(kg/m2).
• A subject provide written informed consent which he voluntarily confirms willingness to participate in a study, having been informed of the full details of the study and comply with the protocol.
• A subject who is eligible according to investigator's assessment

Exclusion Criteria:

• History or presence of clinically significant medical or psychiatric condition or disease.
• History of gastrointestinal disease and resection
• Hypersensitivity to ingredient of investigational product(IP) and other medication, food.
• Genetic Problem such as Galactose intolerance, Lapp lactase deficiency or Glucose-galactose malabsorption.
• A subject who take a drug that inhibit or induce significantly Drug-Metabolizing Enzyme within 1months.
• Positive results for serum examination(HIV, B and C viral test, Syphilis).
• Seated BP is less than 100/65 mmHg or greater than 140/90 mmHg at screening.
• Participation in any other study within 3months.
• History of whole blood donation within 2months and Apheresis 2 weeks.